Health Logic Interactive Inc. (“Health Logic” or the “Company”) (TSXV: CHIP.H)(OTCPK: CHYPF) has reported positive preliminary proof-of-concept test results of its first urine creatinine chip prototype (uC-Chip beta version), which successfully validated the clinically relevant detection range. In parallel to further optimizing and validating the uC-Chip beta version, the Company’s research team is working to advance the design and modeling of the integrated urine albumin-to-creatinine ratio chip (uACR-Chip) prototype.
With these developments, Health Logic Interactive is preparing for its pre-submission meeting with the United States Food and Drug Administration.
“We are proud of our latest achievement: successfully developing an initial prototype of the urine creatinine chip with supported preliminary validation data. This advancement brings us even closer to completion of our uACR-Chip, a lab-on-chip technology that we anticipate will allow for an accurate and sensitive test for chronic kidney disease at point-of-care,” stated David Barthel, CEO Health Logic Interactive Inc.